Our Technology -iTAP-
By combining the biological specificity of antibodies, triggered by external light energy, and the metabolic mechanism in cells, we have created a new therapeutic method, iTAP (intelligent Targeted Antibody Phototherapy), which is our core technology.
We are conducting research and development with the aim of developing new treatment methods with superior efficacy and fewer side effects, mainly in the field of oncology.
iTAP is a minimally invasive cancer therapy achieved by intravenous administration of immunotoxin and photosensitizer with light irradiation to the tumor.
By integrating expertise in antibody design, saporin conjugation, and immunotoxin engineering, we offer a groundbreaking therapeutic platform: iTAP therapy.
Toxin -Enzymatic protein originating from medicinal plants
■ Exerts strong cytotoxic activity against cancer cells as a RIP(ribosome inactivating protein)
■ Overcoming the barrier of expression due to strong cytotoxicity
Immunotoxin
■ Overcoming the technical barriers in developing immunotoxins that were previously difficult to manufacture as pharmaceuticals. ■ Achieving high conjugation efficiency ■ Realizing immunotoxin with homogeneous DAR (Drug-to-Antibody Ratio) ■ Providing the optimal solution for the target cancer
Our strategy focuses on leveraging a broad spectrum of immunotoxins to target treatment-resistant malignancies, including lung cancer, brain tumors, ovarian cancer, and malignant melanoma.
